Start-up Io Finds a [Re]purpose In Cancer, Autoimmune Disease
Like many other development-only biotech start-ups, Io Therapeutics Inc. has built a pipeline from drugs shelved or reprioritized by big pharma in its case, Allergan Inc.
The advantages are clear. Io gets three compounds that all are well defined. "All have U.S. INDs [investigational new drug applications], all have GLP-toxicology data and we have GMP drug supply in hand," said Martin E. Sanders, chairman and CEO of the Santa Ana, Calif.-based firm.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST